Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06265272 · ClinicalTrials.gov registry record
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
A clinical trial of Liver Cirrhosis and Portal Hypertension, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06265272 is a study of Liver Cirrhosis and Portal Hypertension that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 45 participants, below the 1,002-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06265272, a study of Liver Cirrhosis and Portal Hypertension, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis
Conditions Studied
Interventions
- DRUG Injection of a gadolinium contrast agen
- DRUG Radiotracer Injection
- DIAGNOSTIC_TEST Imaging
Study Locations (1)
Massachusetts
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-12-10 |
| Est. Completion | 2026-12-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06265272
The ClinicalTrials.gov registry entry for NCT06265272 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,002-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (96% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver Cirrhosis appearing as the primary indexed condition, and to 3 interventions - of which Injection of a gadolinium contrast agen is the first listed.
NCT06265272 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06265272 about?
NCT06265272 is a clinical study titled "Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis". A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro an...
What is the current status of trial NCT06265272?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2023-12-10. Estimated completion is 2026-12-19.
What conditions does trial NCT06265272 study?
This clinical trial studies the following conditions: Liver Cirrhosis, Portal Hypertension, Hepatic Cell Carcinoma.
What interventions are being tested in trial NCT06265272?
The interventions under investigation include: Injection of a gadolinium contrast agen (DRUG), Radiotracer Injection (DRUG), Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06265272?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06265272 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
RECRUITING · NA
-
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
RECRUITING · Phase 2
-
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
RECRUITING
-
Steroid Free Immunosuppression in Liver Transplantation
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.